Revenue Update on Aegerion Pharmaceuticals(NASDAQ:AEGR)

Aegerion Pharmaceuticals(NASDAQ:AEGR) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $44.53M. Analysts estimated a revenue of $35.50M. Earnings per share were $-0.72. Analysts had estimated an EPS of $-0.38.

Aegerion Pharmaceuticals (AEGR) remained unchanged at the close of Wednesday session. Even as the volume increased to 79,996 ,the shares failed to make any impression and ended at 0 points or 0.00% at $1.56. The trading session commenced at $1.56 and the stock hit a high of $1.59 and touched $1.54 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $19.16 and the 52-week low is $1.23. The company has a market cap of $46 M and has approximately 2,95,14,448 outstanding shares.

Aegerion Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company’s products include Juxtapid (lomitapide) and MYALEPT (metreleptin). Lomitapide is a small molecule microsomal triglyceride transfer protein which is marketed under the brand name Juxtapid (lomitapide) capsules (Juxtapid) in the United States as an adjunct to a low-fat diet and other lipid-lowering treatments. Lomitapide was also approved in the European Union under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for homozygous familial hypercholesterolemia (HoFH) in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor and is available as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *